SUMMARY BACKGROUND DATA: We previously reported, in a study of 608 patients, that the gastric bypass operation (GB) controls type 2 diabetes mellitus in the morbidly obese patient more effectively than any medical therapy. Further, we showed for the first time that it was possible to reduce the mortality from diabetes; GB reduced the chance of dying from 4.5% per year to 1% per year. This control of diabetes has been ascribed to the weight loss induced by the operation. These studies, in weight-stable women, were designed to determine whether weight loss was really the important factor. METHODS: Fasting plasma insulin, fasting plasma glucose, minimal model-derived insulin sensitivity and leptin levels were measured in carefully matched cohorts: six women who had undergone GB and had been stable at their lowered weight 24 to 30 months after surgery versus a control group of six women who did not undergo surgery and were similarly weight-stable. The two groups were matched in age, percentage of fat, body mass index, waist circumference, and aerobic capacity. RESULTS: Even though the two groups of patients were closely matched in weight, age, percentage of fat, and even aerobic capacity, and with both groups maintaining stable weights, the surgical group demonstrated significantly lower levels of serum leptin, fasting plasma insulin, and fasting plasma glucose compared to the control group. Similarly, minimal model-derived insulin sensitivity was significantly higher in the surgical group. Finally, self-reported food intake was significantly lower in the surgical group. CONCLUSIONS: Weight loss is not the reason why GB controls diabetes mellitus. Instead, bypassing the foregut and reducing food intake produce the profound long-term alterations in glucose metabolism and insulin action. These findings suggest that our current paradigms of type 2 diabetes mellitus deserve review. The critical lesion may lie in abnormal signals from the gut.
SUMMARY BACKGROUND DATA: We previously reported, in a study of 608 patients, that the gastric bypass operation (GB) controls type 2 diabetes mellitus in the morbidly obesepatient more effectively than any medical therapy. Further, we showed for the first time that it was possible to reduce the mortality from diabetes; GB reduced the chance of dying from 4.5% per year to 1% per year. This control of diabetes has been ascribed to the weight loss induced by the operation. These studies, in weight-stable women, were designed to determine whether weight loss was really the important factor. METHODS: Fasting plasma insulin, fasting plasma glucose, minimal model-derived insulin sensitivity and leptin levels were measured in carefully matched cohorts: six women who had undergone GB and had been stable at their lowered weight 24 to 30 months after surgery versus a control group of six women who did not undergo surgery and were similarly weight-stable. The two groups were matched in age, percentage of fat, body mass index, waist circumference, and aerobic capacity. RESULTS: Even though the two groups of patients were closely matched in weight, age, percentage of fat, and even aerobic capacity, and with both groups maintaining stable weights, the surgical group demonstrated significantly lower levels of serum leptin, fasting plasma insulin, and fasting plasma glucose compared to the control group. Similarly, minimal model-derived insulin sensitivity was significantly higher in the surgical group. Finally, self-reported food intake was significantly lower in the surgical group. CONCLUSIONS:Weight loss is not the reason why GB controls diabetes mellitus. Instead, bypassing the foregut and reducing food intake produce the profound long-term alterations in glucose metabolism and insulin action. These findings suggest that our current paradigms of type 2 diabetes mellitus deserve review. The critical lesion may lie in abnormal signals from the gut.
Authors: K G MacDonald; S D Long; M S Swanson; B M Brown; P Morris; G L Dohm; W J Pories Journal: J Gastrointest Surg Date: 1997 May-Jun Impact factor: 3.452
Authors: J M Kellum; J F Kuemmerle; T M O'Dorisio; P Rayford; D Martin; K Engle; L Wolf; H J Sugerman Journal: Ann Surg Date: 1990-06 Impact factor: 12.969
Authors: B A Swinburn; B L Nyomba; M F Saad; F Zurlo; I Raz; W C Knowler; S Lillioja; C Bogardus; E Ravussin Journal: J Clin Invest Date: 1991-07 Impact factor: 14.808
Authors: W J Pories; K G MacDonald; E J Morgan; M K Sinha; G L Dohm; M S Swanson; H A Barakat; P G Khazanie; N Leggett-Frazier; S D Long Journal: Am J Clin Nutr Date: 1992-02 Impact factor: 7.045
Authors: N Basso; D Capoccia; M Rizzello; F Abbatini; P Mariani; C Maglio; F Coccia; G Borgonuovo; M L De Luca; R Asprino; G Alessandri; G Casella; F Leonetti Journal: Surg Endosc Date: 2011-06-03 Impact factor: 4.584
Authors: Enrique Lanzarini; Attila Csendes; Hans Lembach; Juan Molina; Luis Gutiérrez; Johanna Silva Journal: World J Surg Date: 2010-09 Impact factor: 3.352
Authors: Mário Nora; Marta Guimarães; Rui Almeida; Paulo Martins; Gil Gonçalves; Maria José Freire; Tiago Ferreira; Cláudia Freitas; Mariana P Monteiro Journal: Obes Surg Date: 2011-11 Impact factor: 4.129
Authors: José Manuel Ramón; Silvia Salvans; Xenia Crous; Sonia Puig; Albert Goday; David Benaiges; Lourdes Trillo; Manuel Pera; Luis Grande Journal: J Gastrointest Surg Date: 2012-03-09 Impact factor: 3.452
Authors: Jing Li; Ritchie J Feuers; Varsha G Desai; Sherry M Lewis; Peter H Duffy; Martha A Mayhugh; George Cowan; Cynthia K Buffington Journal: Obes Surg Date: 2007-06 Impact factor: 4.129